|
Sign In to gain access to subscriptions and/or personal tools.
|
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Ludovico Minati, MSc
Science Direction, unit, Fondazione IRCCS Istituto Nazionale Neurologico "Carlo Besta", Milano, Italy, Neuroradiology, unit, Fondazione IRCCS Istituto Nazionale Neurologico "Carlo Besta", Milano, Italy, lminati{at}istituto-besta.it
Trudi Edginton, PhD
Cognitive Science Research Unit University of Westminster, London, United Kingdom
Maria Grazia Bruzzone, MD
Neuroradiology, unit, Fondazione IRCCS Istituto Nazionale Neurologico "Carlo Besta", Milano, Italy
Giorgio Giaccone, MD
Neuropathology, unit, Fondazione IRCCS Istituto Nazionale Neurologico "Carlo Besta", Milano, Italy
This comprehensive, pedagogically-oriented review is aimed at a heterogeneous audience representative of the allied disciplines involved in research and patient care. After a foreword on epidemiology, genetics, and risk factors, the amyloid cascade model is introduced and the main neuropathological hallmarks are discussed. The progression of memory, language, visual processing, executive, attentional, and praxis deficits, and of behavioral symptoms is presented. After a summary on neuropsychological assessment, emerging biomarkers from cerebrospinal fluid assays, magnetic resonance imaging, nuclear medicine, and electrophysiology are discussed. Existing treatments are briefly reviewed, followed by an introduction to emerging disease-modifying therapies such as secretase modulators, inhibitors of Abeta aggregation, immunotherapy, inhibitors of tau protein phosphorylation, and delivery of nerve growth factor.
Key Words: Alzheimer's disease neuropathology neuropsychological testing neuroimaging pharmacotherapy
References
- Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiat Psych-Gerichtl Med. 1907;64: 146-148.
- Katzman R. The prevalence and malignancy of Alzheimer's disease: a major killer. Arch Neurol. 1976;33: 217-218.[Abstract/Free Full Text]
- World Health Organization. World Health Report 2003: Shaping the Future. Geneva: WHO; 2003.
- Ferri CP, Prince M., Brayne C. et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366: 2112-2117.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Comas-Herrera A., Wittenberg R., Pickard L., Knapp M. Cognitive impairment in older people: future demand for long-term care services and the associated costs. Int J Geriatr Psychiatry. 2007;22:1037-1045.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16:770-778.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Serretti A., Olgiati P., De Ronchi D. Genetics of Alzheimer's disease. A rapidly evolving field. J Alzheimers Dis. 2007;12:73-92.[Web of Science][Medline]
[Order article via Infotrieve]
- Goate A., Chartier-Harlin MC, Mullan M., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.[CrossRef][Medline]
[Order article via Infotrieve]
- Papassotiropoulos A., Fountoulakis M., Dunckley T., et al. Genetics, transcriptomics and proteomics of Alzheimer's disease. J Clin Psychiatry. 2006;67:652-670.[Web of Science][Medline]
[Order article via Infotrieve]
- Irizarry MC, Deng A., Lleo A., et al. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem. 2004;90:1132-1143.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.[Abstract/Free Full Text]
- Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180-184.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Blomqvist ME, Chalmers K., Andreasen N., et al. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging. 2005;26:795-802.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hiltunen M., Lu A., Thomas AV, et al. Ubiquilin 1 modulates amyloid precursor protein trafficking and amyloid-b secretion. J Biol Chem. 2006;281:32240-32253.[Abstract/Free Full Text]
- Rogaeva E., Meng Y., Lee JH, et al. The neuronal sortilinrelated receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168-177.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dreses-Werringloer U., Lambert JC, Vingtdeux V., et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell. 2008;133:1149-1161.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Farkas E., Luiten PG Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol. 2001;64:575-611.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Longstreth WT Jr, Dulberg C., Manolio TA, et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke. 2002;33:2376-2382.[Abstract/Free Full Text]
- Vermeer SE, Prins ND, den Heijer T., et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.[Abstract/Free Full Text]
- Van Den Heuvel C., Thornton E., Vink R. Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res. 2007;161:303-316.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ownby RL, Crocco E., Acevedo A., et al. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530-538.[Abstract/Free Full Text]
- Geerlings MI, den Heijer T., Koudstaal PJ, et al. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology. 2008;70:1258-1264.[Abstract/Free Full Text]
- Koepsell TD, Kurland BF, Harel O., et al. Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology. 2008;70:1732-1739.[Abstract/Free Full Text]
- Hardy J., Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356.[Abstract/Free Full Text]
- Nathalie P., Jean-Noël O. Processing of amyloid precursor protein and amyloid peptide neurotoxicity. Curr Alzheimer Res. 2008;5:92-99.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Matsui T., Ingelsson M., Fukumoto H., et al. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res. 2007;1161:116-123.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Asai M., Hattori C., Szabo B., et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun. 2003;301: 231-235.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cole SL, Vassar R. BACE1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res. 2008;5:100-120.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Stockley JH, O'Neill C. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain. Biochem Soc Trans. 2007;35:574-576.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Postina R. A closer look at alpha-secretase. Curr Alzheimer Res. 2008;5:179-186.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kaether C., Haass C., Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis. 2006;3:275-283.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- El-Agnaf OM, Mahil DS, Patel BP, Austen BM Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. Biochem Biophys Res Commun. 2000;273:1003-1007.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Zhang L., Song L., Terracina G., et al. Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides. Biochemistry. 2001;40:5049-5055.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yin YI, Bassit B., Zhu L., et al. {gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: Implications For Alzheimer Disease. J Biol Chem. 2007;282:23639-23644.[Abstract/Free Full Text]
- Carson JA, Turner AJ Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem. 2002;81:1-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Meyer-Luehmann M., Spires-Jones TL, Prada C., et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720-724.[CrossRef][Medline]
[Order article via Infotrieve]
- Haass C., Selkoe DJ Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8: 101-112.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Brion JP The role of neurofibrillary tangles in Alzheimer disease. Acta Neurol Belg. 1998;98:165-174.[Web of Science][Medline]
[Order article via Infotrieve]
- Sorrentino G., Bonavita V. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. Neurol Sci. 2007;28:63-71.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.[CrossRef][Medline]
[Order article via Infotrieve]
- Berg L., McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326-335.[Abstract/Free Full Text]
- Eriksen JL, Janus CG Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet. 2007;37:79-100.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mott RT, Hulette CM Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am. 2005;15:755-765.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Duyckaerts C., Dickson DW Neuropathology of Alzheimer's disease. In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press; 2003.
- Tagliavini F., Giaccone G., Frangione B., Bugiani O. Pre-amyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neurosci Lett. 1988;93:191-196.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Braak H., Braak E., Grundke-Iqbal I., Iqbal K. Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett. 1986;65:351-355.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Delaère P., He Y., Fayet G., Duyckaerts C., Hauw JJ Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol Aging. 1993;14:191-194.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hof PR, Glannakopoulos P., Bouras C. The neuropathological changes associated with normal brain aging. Histol Histopathol. 1996;11:1075-1088.[Web of Science][Medline]
[Order article via Infotrieve]
- Blessed G., Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.[Abstract/Free Full Text]
- Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351-357.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Goedert M. Tau protein and neurodegeneration. Semin Cell Dev Biol. 2004;15:45-49.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Näslund J., Haroutunian V., Mohs R., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283: 1571-1577.[Abstract/Free Full Text]
- Perry EK, Tomlinson BE, Blessed G., et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978;2:1457-1459.[Abstract/Free Full Text]
- Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10: 122-126.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wu D., Hersh LB Choline acetyltransferase: celebrating its fiftieth year. J Neurochem. 1994;62:1653-1663.[Web of Science][Medline]
[Order article via Infotrieve]
- Storey E., Kinsella GJ, Slavin MJ The neuropsychological diagnosis of Alzheimer's disease. J Alzheimers Dis. 2001;3:261-285.[Medline]
[Order article via Infotrieve]
- Small BJ, Mobly JL, Laukka EJ, et al. Cognitive deficits in preclinical Alzheimer's disease. Acta Neurol Scand Suppl. 2003;179:29-33.[Medline]
[Order article via Infotrieve]
- Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56:303-308.[Abstract/Free Full Text]
- Gauthier S., Reisberg B., Zaudig M., et al. Mild cognitive impairment. Lancet. 2006;367:1262-1270.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Beatty WW, Salmon DP, Butters N., et al. Retrograde amnesia in patients with Alzheimer's disease or Huntington's disease. Neurobiol Aging. 1988;9:181-186.[Web of Science][Medline]
[Order article via Infotrieve]
- Jones S., Livner A., Bäckman L. Patterns of prospective and retrospective memory impairment in preclinical Alzheimer's disease. Neuropsychology. 2006;20:144-152.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Damasio AR Time-locked multiregional retroactivation: a systems level proposal for the neural substrates of recall and recognition. Cognition. 1989;33:25-62.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Squire LR, Alvarez P. Retrograde amnesia and memory consolidation: a neurobiological perspective. Curr Opin Neurobiol. 1995;5:169-77.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 2007;6: 1004-1014.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Moulin CJ, James N., Freeman JE, et al. Deficient acquisition and consolidation: intertrial free recall performance in Alzheimer's disease and mild cognitive impairment. J Clin Exp Neuropsychol. 2004;26:1-10.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pepin EP, Eslinger PJ Verbal memory decline in Alzheimer's disease: a multiple-processes deficit. Neurology. 1989;39:1477-1482.[Abstract/Free Full Text]
- Bayley PJ, Salmon DP, Bondi MW, et al. Comparison of the serial position effect in very mild Alzheimer's disease, mild Alzheimer's disease, and amnesia associated with electroconvulsive therapy. J Int Neuropsychol Soc. 2000;6:290-298.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kensinger EA, Brierley B., Medford N., et al. Effects of normal aging and Alzheimer's disease on emotional memory. Emotion. 2002;2:118-134.[CrossRef][Medline]
[Order article via Infotrieve]
- Vitali P., Minati L., Chiarenza G., et al. The Von Restorff effect in ageing and Alzheimer's disease. Neurol Sci. 2006;27:166-172.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Helkala EL, Laulumaa V., Soininen H., Riekkinen PJ Recall and recognition memory in patients with Alzheimer's and Parkinson's diseases. Ann Neurol. 1988;24: 214-217.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Becker JT, Overman AA The semantic memory deficit in Alzheimer's disease. Rev Neurol. 2002;35:777-783.[Web of Science][Medline]
[Order article via Infotrieve]
- Monsch AU, Bondi MW, Butters N., et al. A comparison of category and letter fluency in Alzheimer's disease and Huntington's disease. Neuropsychologia. 1994;8:25-30.[CrossRef]
- Salmon DP, Heindel WC, Lange KL Differential decline in word generation from phonemic and semantic categories during the course of Alzheimer's disease: implications for the integrity of semantic memory. J Int Neuropsychol Soc. 1999;5:692-703.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hodges J., Patterson KE, Graham N., Dawson K. Naming and knowing in dementia of the Alzheimer's type. Brain Lang. 1996;54:302-325.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dick MB, Nielson K., Beth RE, et al. Acquisition and long-term retention of a fine motor skill in Alzheimer s disease. Brain Cogn. 1995;29:294-306.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Camus JF, Wenisch NE, Blanchard MF, et al. Implicit memory for words presented in short texts is preserved in Alzheimer s disease? Psychol Med. 2003;33:169-174.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Park SM, Gabrieli JD, Reminger SL, et al. Preserved priming across study-test picture transformations in patients with Alzheimer s disease. Neuropsychology. 1998;12:340-352.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kempler D., Curtiss S., Jackson C. Syntactic preservation in Alzheimer's disease. J Speech Hear Res. 1987;30:343-350.[Web of Science][Medline]
[Order article via Infotrieve]
- Murdoch BE, Chenery HJ, Wilks V., Boyle RS Language disorders in dementia of the Alzheimer type. Brain Lang. 1987;31:122-137.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chan AS, Salmon DP Semantic memory deficits associated with Alzheimer's disease. Neuropsychology. 1994;8: 385-394.[CrossRef]
- Emery VO Language impairment in dementia of the Alzheimer type: a hierarchical decline? Int J Psychiatry Med. 2000;30:145-164.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Groves-Wright K., Neils-Strunjas J., Burnett R., et al. A comparison of verbal and written language in Alzheimer's disease. J Commun Disord. 2004;37:109-130.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Glosser G., Kohn SE, Sands L., et al. Impaired spelling in Alzheimer's disease: a linguistic deficit? Neuropsychologia. 1999;37:807-815.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Forbes KE, Shanks MF, Venneri A. The evolution of dysgraphia in Alzheimer's disease. Brain Res Bull. 2004;63: 19-24.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kaskie B., Storandt M. Visuospatial deficit in dementia of the Alzheimer type. Arch Neurol. 1995;52:422-425.[Abstract/Free Full Text]
- Fujimori M., Imamura T., Yamashita H., et al. The disturbances of object vision and spatial vision in Alzheimer's disease. Dementia Geriat Cog Disord. 1997;8:228-231.[CrossRef]
- Binetti G., Cappa SF, Magni E., et al. Visual and spatial perception in the early phase of Alzheimer's disease. Neuropsychology. 1998;12:29-33.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Laatu S., Revonsuo A., Jäykkä H., et al. Visual object recognition in early Alzheimer's disease: deficits in semantic processing. Acta Neurol Scand. 2003;108:82-89.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kurylo DD, Corkin S., Growdon JH Perceptual organization in Alzheimer's disease. Psychol Aging. 1994;9:562-567.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mendez MF, Ghajarania M., Perryman KM Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14:33-40.[Web of Science][Medline]
[Order article via Infotrieve]
- Lafleche G., Albert MS Executive function deficits in mild Alzheimer's disease. Neuropsychology. 1995;9:313-320.[CrossRef][Web of Science]
- Perry RJ, Hodges JR Attention and executive deficits in Alzheimer's disease. A critical review. Brain. 1999;122: 383-404.[Abstract/Free Full Text]
- Collette F., Van der Linden M., Salmon E. Executive dysfunction in Alzheimer's disease. Cortex. 1999;35: 57-72.[Web of Science][Medline]
[Order article via Infotrieve]
- Baudic S., Barba GD, Thibaudet MC, et al. Executive function deficits in early Alzheimer's disease and their relations with episodic memory. Arch Clin Neuropsychol. 2006;21:15-21.[Abstract]
- Patterson MB, Mack JL, Geldmacher DS, Whitehouse PJ Executive functions and Alzheimer's disease: problems and prospects. Eur J Neurol. 1996;3: 5-15.
- Baddeley AD, Baddeley HA, Bucks RS, et al. Attentional control in Alzheimer's disease. Brain. 2001;124: 1492-508.[Abstract/Free Full Text]
- Parasuraman R., Greenwood PM, Haxby JV, et al. Visuospatial attention in dementia of the Alzheimer type. Brain. 1992;115:711-733.[Abstract/Free Full Text]
- Perry RJ, Watson P., Hodges JR The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia. 2000;38:252-271.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Capitani E., Della Sala S., Lucchelli F., et al. Perceptual attention in aging and dementia measured by Gottschaldt's Hidden Figure Test. J Gerontol. 1988;43: 157-163.
- Filoteo JV, Delis DC, Massman PJ, et al. Directed and divided attention in Alzheimer s disease: impairment in shifting of attention to global and local stimuli. J Clin Exp Neuropsychol. 1992;14:871-883.[Web of Science][Medline]
[Order article via Infotrieve]
- Parasuraman R., Greenwood PM, Alexander GE Alzheimer disease constricts the dynamic range of spatial attention in visual search. Neuropsychologia. 2000;38: 1126-1135.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mendez M., Cherrier M., Cymerman J. Hemispatial neglect on visual search tasks in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol. 1997;10: 203-208.[Web of Science][Medline]
[Order article via Infotrieve]
- Berardi AM, Parasuraman R., Haxby JV Sustained attention in mild Alzheimer's disease. Dev Neuropsychol. 2005;28:507-537.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Edwards DF, Deuela RK, Bauma CM, Morrisa JC A Quantitative Analysis of Apraxia in Senile Dementia of the Alzheimer Type: Stage-Related Differences in Prevalence and Type. Dement Geriatr Cogn Disord. 1991;2:142-149.[CrossRef]
- Della Sala S., Lucchelli F., Spinnler H. Ideomotor apraxia in patients with dementia of Alzheimer type. J Neurol. 1987;234:91-93.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dumont C., Ska B., Joanette Y. Conceptual apraxia and semantic memory deficit in Alzheimer's disease: two sides of the same coin? J Int Neuropsychol Soc. 2000;6:693-703.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lucchelli F., Lopez OL, Faglioni P., Boller F. Ideomotor and ideational apraxia in alzheimer's disease. Int J Ger Psych. 2004;8:413-417.[CrossRef]
- Jacobs DH, Adair JC, Williamson DJ, et al. Apraxia and motor-skill acquisition in Alzheimer's disease are dissociable. Neuropsychologia. 1999;37:875-880.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Capone JG, Della Sala S., Spinnler H., et al. Upper and lower face and ideomotor apraxia in patients with Alzheimer's disease. Behav Neurol. 2003;14:1-8.[Web of Science][Medline]
[Order article via Infotrieve]
- Smith MZ, Esiri MM, Barnetson L., et al. Constructional apraxia in Alzheimer's disease: association with occipital lobe pathology and accelerated cognitive decline. Dement Geriatr Cogn Disord. 2001;12: 281-288.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Guérin F., Belleville S., Ska B. Characterization of visuoconstructional disabilities in patients with probable dementia of Alzheimer's type. J Clin Exp Neuropsychol. 2002;24:1-17.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kwak YT "Closing-in" phenomenon in Alzheimer's disease and subcortical vascular dementia. BMC Neurol. 2004;4:3.[CrossRef][Medline]
[Order article via Infotrieve]
- Jost BC, Grossberg GT The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc. 1996;44:1078-1081.[Web of Science][Medline]
[Order article via Infotrieve]
- Mega MS, Cummings JL, Fiorello T., Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130-135.[Abstract/Free Full Text]
- Ballard C., Ayre G., Gray A. Psychotic symptoms and behavioral disturbances in dementia: A review. Rev Neurol. 1999;155:44-52.
- Starkstein SE, Jorge R., Mizrahi R., Robinson RG The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry. 2005;162:2086-2093.[Abstract/Free Full Text]
- Gilley DW, Bienias JL, Wilson RS, et al. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol Med. 2004;34:1129-1135.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Shimabukuro J., Awata S., Matsuoka H. Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients. Psychiatry Clin Neurosci. 2005;59:274-279.[Medline]
[Order article via Infotrieve]
- Cole CS, Richards KC Sleep and cognition in people with Alzheimer's disease. Issues Ment Health Nurs. 2005;26:687-698.[CrossRef][Medline]
[Order article via Infotrieve]
- Starkstein SE, Migliorelli R., Tesón A., et al. Prevalence and clinical correlates of pathological affective display in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1995;59:55-60.[Abstract/Free Full Text]
- Derouesné C., Piquard A., Thibault S., et al. Noncognitive symptoms in Alzheimer's disease. A study of 150 community-dwelling patients using a questionnaire completed by the caregiver. Rev Neurol (Paris). 2001;157:162-177.[Medline]
[Order article via Infotrieve]
- Raskind MA, Peskind ER Neurobiologic bases of non-cognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994;8:54-60.[Web of Science][Medline]
[Order article via Infotrieve]
- Shinosaki K., Nishikawa T., Takeda M. Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatry Clin Neurosci. 2000;54:611-620.[Medline]
[Order article via Infotrieve]
- Pomara N., Greenberg WM, Branford MD, Doraiswamy PM Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update. Psychopharmacol Bull. 2003;37:120-134.[Medline]
[Order article via Infotrieve]
- Garcia-Alloza M., Hirst WD, Chen CP, et al. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology. 2004;29:410-416.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lai MK, Tsang SW, Alder JT, et al. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl). 2005;179: 73-677.
- Lee DY, Choo IH, Jhoo JH, et al. Frontal dysfunction underlies depressive syndrome in Alzheimer disease: a FDG-PET study. Am J Geriatr Psychiatry. 2006;14: 625-628.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Levy-Cooperman N., Burhan AM, Rafi-Tari S., et al. Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease. J Psychiatry Neurosci. 2008;33: 218-226.[Web of Science][Medline]
[Order article via Infotrieve]
- Sun X., Steffens DC, Au R., et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry. 2008;65:542-550.[Abstract/Free Full Text]
- Wilson RS, Arnold SE, Beck TL, et al. Change in depressive symptoms during the prodromal phase of Alzheimer disease. Arch Gen Psychiatry. 2008;65:439-445.[Abstract/Free Full Text]
- Kalbe E., Salmon E., Perani D., et al. Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment. Dement Geriatr Cogn Disord. 2005;19: 349-356.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Harwood DG, Sultzer DL, Wheatley MV Impaired insight in Alzheimer disease: association with cognitive deficits, psychiatric symptoms, and behavioral disturbances. Neuropsychiatry Neuropsychol Behav Neurol. 2000;13:83-88.[Web of Science][Medline]
[Order article via Infotrieve]
- Gil R., Arroyo-Anllo EM, Ingrand P., et al. Self-consciousness and Alzheimer's disease. Acta Neurol Scand. 2001;104:296-300.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sato J., Nakaaki S., Murata Y., et al. Two dimensions of anosognosia in patients with Alzheimer's disease: reliability and validity of the Japanese version of the Anosognosia Questionnaire for Dementia (AQ-D). Psychiatry Clin Neurosci. 2007;61:672-677.[Medline]
[Order article via Infotrieve]
- McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.[Abstract/Free Full Text]
- World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 1992.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
- Folstein MF, Folstein SE, McHugh PR "Mini-Mental State" A Practical Method for Grading the Cognitive State of patients for the Clinician. J Psychiat Res. 1975;12:189-198.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rosen WG, Mohs RC, Davis KL A new rating scale for Alzheimer's disease. Am J Psychiatr. 1984;141: 1356-1364.[Abstract/Free Full Text]
- Morris JC, Heyman A., Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159-1165.[Abstract/Free Full Text]
- Saykin AJ, Janssen RS, Sprehn GC, et al. Longitudinal evaluation of neuropsychological function in homosexual men with HIV infection: 18-month follow-up. J Neuropsychiatry Clin Neurosci. 1991;3:2860-298.
- Cummings JL, Mega M., Gray K., et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44: 2308-2314.[Abstract/Free Full Text]
- Olin JT, Katz IR, Meyers BS, et al. Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002;10:129-141.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Alexopoulos GS, Abrams RC, Young RC, Shamoian CA Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988;23:271-284.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mayer LS, Bay RC, Politis A., et al. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS. Int J Geriatr Psychiatry. 2006;21:930-936.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Teng E., Ringman JM, Ross LK, et al. Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. Am J Geriatr Psychiatry. 2008;16:469-477.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Reisberg B., Ferris SH, Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139.[Abstract/Free Full Text]
- Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull. 1988;24:637-639.[Web of Science][Medline]
[Order article via Infotrieve]
- Maddrey AM, Cullum CM, Weiner MF, Filley CM Premorbid intelligence estimation and level of dementia in Alzheimer's disease. J Int Neuropsychol Soc. 1996;2:551-555.[CrossRef][Medline]
[Order article via Infotrieve]
- Fox LS, Olin JT, Erblich J., et al. Severity of cognitive impairment in Alzheimer's disease affects list learning using the California Verbal Learning Test (CVLT). Int J Geriatr Psychiatry. 1998;13:544-549.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hogervorst E., Combrinck M., Lapuerta P., et al. The Hopkins Verbal Learning Test and screening for dementia. Dement Geriatr Cogn Disord. 2002;13: 13-20.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Barzotti T., Gargiulo A., Marotta MG, et al. Correlation between cognitive impairment and the Rey auditory-verbal learning test in a population with Alzheimer disease. Arch Gerontol Geriatr Suppl. 2004;9:57-62.[Medline]
[Order article via Infotrieve]
- Lowndes G., Savage G. Early detection of memory impairment in Alzheimer's disease: a neurocognitive perspective on assessment. Neuropsychol Rev. 2007;17: 193-202.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bigler ED, Rosa L., Schultz F., et al. Rey-Auditory Verbal Learning and Rey-Osterrieth Complex Figure Design performance in Alzheimer's disease and closed head injury. J Clin Psychol. 1989;45:277-280.[Web of Science][Medline]
[Order article via Infotrieve]
- Cahn DA, Salmon DP, Monsch AU, et al. Screening for dementia of the alzheimer type in the community: the utility of the Clock Drawing Test. Arch Clin Neuropsychol. 1996;11:529-539.[Abstract]
- Carlesimo GA, Fadda L., Lorusso S., Caltagirone C. Verbal and spatial memory spans in Alzheimer's and multi-infarct dementia. Acta Neurol Scand. 1994;89: 132-138.[Web of Science][Medline]
[Order article via Infotrieve]
- Wilson B., Cockburn J., Baddeley A., Hiorns R. The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol. 1989;11:855-870.[Web of Science][Medline]
[Order article via Infotrieve]
- Kazui H., Matsuda A., Hirono N., et al. Everyday memory impairment of patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2005;19:331-337.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Binetti G., Magni E., Padovani A., et al. Executive dysfunction in early Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996;60:91-93.[Abstract/Free Full Text]
- Nagahama Y., Okina T., Suzuki N., et al. Factor structure of a modified version of the Wisconsin card sorting test: an analysis of executive deficit in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord. 2003;16:103-112.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Amieva H., Lafont S., Rouch-Leroyer I., et al. Evidencing inhibitory deficits in Alzheimer's disease through interference effects and shifting disabilities in the Stroop test. Arch Clin Neuropsychol. 2004;19:791-803.[Abstract/Free Full Text]
- Stokholm J., Vogel A., Gade A., Waldemar G. Heterogeneity in executive impairment in patients with very mild Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22:54-59.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Houston WS, Delis DC, Lansing A., et al. Executive function asymmetry in older adults genetically at-risk for Alzheimer's disease: verbal versus design fluency. J Int Neuropsychol Soc. 2005;11:863-870.[Web of Science][Medline]
[Order article via Infotrieve]
- Hodges JR, Salmon DP, Butters N. The nature of the naming deficit in Alzheimer's and Huntington's disease. Brain. 1991;114:1547-1558.[Abstract/Free Full Text]
- Travniczek-Marterer A., Danielczyk W., Simanyi M., Fischer P. Ideomotor apraxia in Alzheimer's disease. Acta Neurol Scand. 1993;88:1-4.[Medline]
[Order article via Infotrieve]
- Hodges JR, Patterson K. Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications. Neuropsychologia. 1995;33:441-459.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Plassman BL, Khachaturian AS, Townsend JJ, et al. Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. Alzheimers Dement. 2006;2:2-11.[Medline]
[Order article via Infotrieve]
- Dubois B., Feldman HH, Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6: 734-746.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mayeux R., Saunders AM, Shea S., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998;338:506-511.[Abstract/Free Full Text]
- McConnell LM, Sanders GD, Owens DK Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. Genet Test. 1999;3:47-53.[Web of Science][Medline]
[Order article via Infotrieve]
- Sunderland T., Hampel H., Takeda M., et al. Biomarkers in the diagnosis of Alzheimer's disease: are we ready? J Geriatr Psychiatry Neurol. 2006;19:172-179.[Abstract/Free Full Text]
- Galasko D., Chang L., Motter R., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937-945.[Abstract/Free Full Text]
- Steinerman JR, Honig LS Laboratory biomarkers in Alzheimer's disease. Curr Neurol Neurosci Rep. 2007;7:381-387.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sjogren M., Minthon L., Davidsson P., et al. CSF Levels of tau,b-amyloid-42 and GAP-43 in Frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 2000;107:563-576.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Vandermeeren M., Merken Vanmechelen J., Six A., et al. Detection of TAU proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828-1834.[Web of Science][Medline]
[Order article via Infotrieve]
- Blennow K., Wallin A., Agren H., et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer's disease. Mol Chem Neuropathology. 1995;26:231-245.
- Itoh N., Arai H., Urakami K., et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001;50:150-156.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Minati L., Grisoli M., Bruzzone MG MR spectroscopy, functional MRI, and diffusion-tensor imaging in the aging brain: a conceptual review. J Geriatr Psychiatry Neurol. 2007;20:3-21.[Abstract/Free Full Text]
- Lehéricy S., Marjanska M., Mesrob L., et al. Magnetic resonance imaging of Alzheimer's disease. Eur Radiol. 2007;17:347-362.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Petersen RC, Knopman D., Boeve BF, et al. Role of hippocampal volumes in predicting progression to mild cognitive impairment. Neurology. 2005;64:126-127.
- Schuff N., Amend D., Ezekiel F., et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology. 1997;49:1513-1521.[Abstract/Free Full Text]
- Catani M., Cherubini A., Howard R., et al. (1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport. 2001;12:2315-2317.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hanyu H., Sakurai H., Iwamoto T., et al. Diffusion-weighted MR imaging of the hippocampus and temporal white matter in Alzheimer's disease. J Neurol Sci. 1998;156:195-200.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kantarci K., Jack CR, Xu YC, et al. Mild cognitive impairment and Alzheimer disease: regional diffusivity of water. Radiology. 2001;219:101-107.[Abstract/Free Full Text]
- Bozzali M., Falini A., Franceschi M., et al. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2002;72:742-746.[Abstract/Free Full Text]
- Yoshiura T., Mihara F., Ogomori K., et al. Diffusion tensor in posterior cingulate gyrus: correlation with cognitive decline in Alzheimer's disease. Neuroreport. 2002;13:2299-2302.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kantarci K., Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2005;64: 902-904.[Abstract/Free Full Text]
- Sandson TA, O'Connor M., Sperling RA, et al. Non-invasive perfusion MRI in Alzheimer's disease: a preliminary report. Neurology. 1996;47:1339-1342.[Abstract/Free Full Text]
- Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol. 2000;47: 93-100.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404-411.[Abstract/Free Full Text]
- Dickerson BC, Sperling RA Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. Neuropsychologia. 2008;46:1624-1635.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450-456.[Abstract/Free Full Text]
- Rombouts SA, Barkhof F., Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;73:665-671.[Abstract/Free Full Text]
- Kircher TT, Erb M., Grodd W., Leube DT Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. Am J Geriatr Psychiatry. 2005;13:1006-1013.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Greicius MD, Srivastava G., Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101: 4637-4642.[Abstract/Free Full Text]
- Matsuda H. Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med. 2007;48:1289-1300.[Abstract/Free Full Text]
- Matsuda H., Kanetaka H., Ohnishi T., et al. Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging. 2002;29:1502-1505.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Jagust W., Thisted R., Devous MD, et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology. 2001;56: 950-956.[Abstract/Free Full Text]
- Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002;29:615-622.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Bonte FJ, Harris TS, Roney CA, Hynan LS Differential diagnosis between Alzheimer's and frontotemporal disease by the posterior cingulate sign. J Nucl Med. 2004;45:771-774.[Abstract/Free Full Text]
- Caroli A., Testa C., Geroldi C., et al. Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. J Neurol. 2007;254:1698-1707.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486-510.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mosconi L., Brys M., Glodzik-Sobanska L., et al. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol. 2007;42:129-138.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mosconi L., Tsui WH, Santi S., et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology. 2005;64:1860-1867.[Abstract/Free Full Text]
- Santi S., Leon MJ, Rusinek H., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging. 2001;22:529-539.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chetelat G., Desgranges B., de la Sayette V., et al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60:1374-1377.[Abstract/Free Full Text]
- Minoshima S., Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130: 2616-2635.[Abstract/Free Full Text]
- Mosconi L., Tsui WH, Herholz K., et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49:390-398.[Abstract/Free Full Text]
- Shoghi-Jadid K., Small D., Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brain of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Klunk WE, Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Verhoeff NP, Wilson AA, Takeshita S., et al. In vivo imaging of Alzheimer disease beta-amyloid with [11C]SB13 PET. Am Geriatr Psychiatry. 2004;12:584-595.
- Kudo Y., Okamura N., Forumoto S., et al. 2-(2-[2-Dimethylaminothiazol-5-yl]-ethenyl)-6-(2-[fluoro]ethoxy) benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med. 2007;49:554-561.
- Nordberg A. Amyloid imaging in Alzheimer's disease. Curr Opin Neurol. 2007;20:398-402.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205-1212.[Abstract/Free Full Text]
- Lockhart A., Lamb JR, Osredkar T., et al. PIB is a nonspecific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130: 2607-2615.[Abstract/Free Full Text]
- Nordberg A., Lundqvist H., Hartvig P., et al. Kinetic analysis of regional (S)-11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord. 1995;9:21-27.[Web of Science][Medline]
[Order article via Infotrieve]
- Rosén I. Electroencephalography as a diagnostic tool in dementia. Dement Geriatr Cogn Disord. 1997;8:110-116.[Web of Science][Medline]
[Order article via Infotrieve]
- Jeong J. EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol. 2004;115:1490-505.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Adler G. The EEG as an indicator of cholinergic deficit in Alzheimer's disease. Fortschr Neurol Psychiatr. 2000;68:352-356.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hooijer C., Jonker C., Posthuma J., Visser SL Reliability, validity and follow-up of the EEG in senile dementia: sequelae of sequential measurement. Electroencephalogr Clin Neurophysiol. 1990;76:400-412.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rosén I., Gustafson L., Risberg J. Multichannel EEG frequency analysis and somatosensory-evoked potentials in patients with different types of organic dementia. Dementia. 1993;4:43-49.[Web of Science][Medline]
[Order article via Infotrieve]
- Jelic V., Shigeta M., Julin P., et al. Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Dementia. 1996;7:314-323.[Web of Science][Medline]
[Order article via Infotrieve]
- Olichney JM, Hillert DG Clinical applications of cognitive event-related potentials in Alzheimer's disease. Phys Med Rehabil Clin N Am. 2004;15:205-233.[Medline]
[Order article via Infotrieve]
- Swanwick GR, Rowan MJ, Coen RF, et al. Prognostic value of electrophysiological markers in Alzheimer's disease. Am J Geriatr Psychiatry. 1999;7:335-338.[Web of Science][Medline]
[Order article via Infotrieve]
- Ford JM, Askari N., Mathalon DH, et al. Event-related brain potential evidence of spared knowledge in Alzheimer's disease. Psychol Aging. 2001;16:161-176.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yokoyama Y., Nakashima K., Shimoyama R., et al. Distribution of event-related potentials in patients with dementia. Electromyogr Clin Neurophysiol. 1995;35: 431-437.[Medline]
[Order article via Infotrieve]
- Pfefferbaum A., Wenegrat BG, Ford JM, et al. Clinical application of the P3 component of event-related potentials: II. dementia, depression and schizophrenia. Electroencephalogr Clin Neurophysiol. 1984;59:104-124.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Polich J., Pitzer A. P300 and Alzheimer's disease: odd-ball task difficulty and modality effects. Electroencephalogr Clin Neurophysiol. 1999;50:281-287.[Web of Science]
- Iragui V., Kutas M., Salmon DP Event-related brain potentials during semantic categorization in normal aging and senile dementia of the Alzheimer's type. Electroencephalogr Clin Neurophysiol. 1996;100:392-406.[Medline]
[Order article via Infotrieve]
- Ford JM, Woodward SH, Sullivan EV, et al. N400 evidence of abnormal responses to speech in Alzheimer's disease. Electroencephalogr Clin Neurophysiol. 1996;99: 235-246.[Web of Science][Medline]
[Order article via Infotrieve]
- Growdon JH, Corkin S. Neurochemical approaches to the treatment of senile dementia. Proc Annu Meet Am Psychopathol Assoc. 1980;69:281-296.[Medline]
[Order article via Infotrieve]
- Scarpini E., Scheltens P., Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003;2:539-547.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Klafki HW, Staufenbiel M., Kornhuber J., Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain. 2006;129:2840-2855.[Abstract/Free Full Text]
- Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136-145.[Abstract/Free Full Text]
- Rösler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633-638.[Abstract/Free Full Text]
- Raskind MA, Peskind ER, Wessel T., Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000;54: 2261-2268.[Abstract/Free Full Text]
- Samochocki M., Höffle A., Fehrenbacher A., et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 2003;305:1024-1036.[Abstract/Free Full Text]
- Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:295-300.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Birks J., Iakovidou V., Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2000; CD001191.
- Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2003; CD001190.
- Loy C., Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2004; CD001747.
- Bullock R., Touchon J., Bergman H., et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005;21:1317-1327.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006; CD005593.
- Burns A., O'Brien J., Auriacombe S., et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20:732-755.[Abstract/Free Full Text]
- Gotti C., Riganti L., Vailati S., Clementi F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr Pharm Des. 2006;12:407-428.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Palmer GC Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets. 2001;2:241-271.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Parsons CG, Stöffler A., Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699-723.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Johnson JW, Kotermanski SE Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6:61-67.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.[Abstract/Free Full Text]
- McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006; CD003154.
- Porsteinsson AP, Grossberg GT, Mintzer J., Olin JT, for the Memantine Mem-Md-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83-89.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gauthier S., Feldman H., Hecker J., et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2002;14:389-404.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cummings JL, Koumaras B., Chen M., et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother. 2005;3:137-148.[CrossRef][Medline]
[Order article via Infotrieve]
- Herrmann N., Rabheru K., Wang J., Binder C. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005;13:527-534.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gauthier S., Wirth Y., Möbius HJ Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20:459-464.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cummings JL, Schneider E., Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006;67:57-63.[Abstract/Free Full Text]
- Borson S., Raskind MA Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology. 1997;48:17-24.
- Knopman DS Part VII. Treatment of neuropsychiatric symptoms in Alzheimer's disease. Dis Mon. 2000;46: 761-766.[CrossRef][Medline]
[Order article via Infotrieve]
- Daiello LA Atypical antipsychotics for the treatment of dementia-related behaviors: an update. Med Health R I. 2007;90:191-194.[Medline]
[Order article via Infotrieve]
- Ballard C., Lana MM, Theodoulou M., et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5:e76.[CrossRef][Medline]
[Order article via Infotrieve]
- Meyers BS, Mei-Tal V. Psychiatric reactions during tricyclic treatment of the elderly reconsidered. J Clin Psychopharmacol. 1983;3:2-6.[Web of Science][Medline]
[Order article via Infotrieve]
- Nyth AL, Gottfries CG, Lyby K., et al. A controlled multicenter clinical study of citalopram and placebo in elderly patients with and without concomitant dementia. Acta Psychiatrica Scandinavica. 1992;86: 138-145.[Web of Science][Medline]
[Order article via Infotrieve]
- Petracca GM, Chemerinski E., Starkstein SE A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int. Psychogeriatrics. 2001;13:233-240.
- Lyketsos CG, DelCampo L., Steinberg M., et al. Treating depression in Alzheimer Disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60: 737-746.[Abstract/Free Full Text]
- Grau-Veciana JM Treatment of non cognitive symptoms of Alzheimer's disease. Rev Neurol. 2006;42: 482-488.[Web of Science][Medline]
[Order article via Infotrieve]
- Mittelman MS, Ferris SH, Shulman E., et al. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA. 1996;276:1725-1731.[Abstract/Free Full Text]
- De Vreese LP, Neri M., Fioravanti M., et al. Memory rehabilitation in Alzheimer's disease: a review of progress. Int J Geriatr Psychiatry. 2001;16:794-809.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Fossey J., Ballard C., Juszczak E., et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332:756-761.[Abstract/Free Full Text]
- Grossberg GT The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr. 2002;14:27-49.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wilson BA, Evans JJ, Emslie H., Malinek V. Evaluation of NeuroPage: a new memory aid. J Neurol Neurosurg Psychiatry. 1997;63:113-115.[Abstract/Free Full Text]
- Clare L., Wilson BA, Carter G., et al. Intervening with everyday memory problems in dementia of Alzheimer type: an errorless learning approach. J Clin Exp Neuropsychol. 2000;22:132-146.[Web of Science][Medline]
[Order article via Infotrieve]
- Spector A., Thorgrimsen L., Woods B., et al. Efficacy of an evidence -based cognitive stimulation therapy programme for people with dementia Randomised controlled trial. Br J Psychiatry. 2003;183:248-254.[Abstract/Free Full Text]
- Berry E., Kapur N., Williams L., et al. The use of a wearable camera, SenseCam, as a pictorial diary to improve autobiographical memory in a patient with limbic encephalitis: a preliminary report. Neuropsychol Rehabil. 2007;17:582-601.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Woods RT Discovering the person with Alzheimer's disease: cognitive, emotional and behavioural aspects. Aging Ment Health. 2001;5:S7-S16.[CrossRef][Medline]
[Order article via Infotrieve]
- Kitwood T., Bredin K. Towards a theory of dementia care: personhood and well-being. Ageing Soc. 1992;12: 269-287.[Medline]
[Order article via Infotrieve]
- McGeer PL, McGeer EG NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639-647.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mintzer JE, Wilcock GK, Black SE, et al. P2-412 MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease (AD): Analysis from a 12-month phase 2 trial. Alz Dem. 2007;3:99-100.
- Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008;7:483-493.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Weggen S., Rogers M., Eriksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci. 2007;28:536-543.[CrossRef][Medline]
[Order article via Infotrieve]
- Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:71-77.[Medline]
[Order article via Infotrieve]
- Zhou B., Teramukai S., Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23: 194-201.[Web of Science][Medline]
[Order article via Infotrieve]
- Li G., Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69:878-885.[Abstract/Free Full Text]
- Arvanitakis Z., Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795-1802.[Abstract/Free Full Text]
- Wolozin B., Manger J., Bryant R., et al. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:63-70.[Medline]
[Order article via Infotrieve]
- Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 2007;282: 26832-26844.[Abstract/Free Full Text]
- Parsons RB, Farrant JK, Price GC, et al. Regulation of the lipidation of beta-secretase by statins. Biochem Soc Trans. 2007;35:577-582.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Jaffe AB, Toran-Allerand CD, Greengard P., et al. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem. 1994;269:13065-13068.[Abstract/Free Full Text]
- Yaffe K., Sawaya G., Lieberburg I., et al. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA. 1998;279:688-695.[Abstract/Free Full Text]
- Hogervorst E., Williams J., Budge M., et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101: 485-512.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- LeBlanc ES, Janowsky J., Chan BKS, et al. Hormone replacement therapy and cognition. Systematic review and meta-analysis. JAMA. 2001;285:1489-1499.[Abstract/Free Full Text]
- Nathan BP, Barsukova AG, Shen F., et al. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology. 2004;145:3065-3073.[Abstract/Free Full Text]
- Shumaker SA, Legault C., Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.[Abstract/Free Full Text]
- Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol. 2004;61:82-88.[Abstract/Free Full Text]
- Maxwell CJ, Hicks MS, Hogan DB, et al. Supplemental use of antioxidant vitamins and subsequent decline and dementia. Dement Geriatr Cogn Disord. 2005;20: 45-51.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gray SL, Anderson ML, Crane PK, et al. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J Am Geriatr Soc. 2008;56:291-295.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Postina R., Schroeder A., Dewachter I., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004;113: 1456-1464.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer's disease-an update. Curr Alzheimer Res. 2007;4:577-580.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Fahrenholz F., Postina R. Alpha-secretase activation-an approach to Alzheimer's disease therapy. Neurodegener Dis. 2006;3:255-261.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Laird FM, Cai H., Savonenko AV, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693-11709.[Abstract/Free Full Text]
- Ghosh AK, Kumaragurubaran N., Hong L., et al. Memapsin 2 (beta-secretase) inhibitors: drug development. Curr Alzheimer Res. 2008;5:121-131.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Iserloh U., Pan J., Stamford AW, et al. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg Med Chem Lett. 2008;18:418-422.[CrossRef][Medline]
[Order article via Infotrieve]
- Imbimbo BP Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem. 2008;8:54-61.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Icad 2008. Alzheimer's Association International Conference on Alzheimer's Disease: Abstract 03-04-01. Presented July 29, 2008.
- Gervais F., Chalifour R., Garceau D., Kong X., Laurin J., Mclaughlin J., Morissette C., Paquette J. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001;8:28-35.[Medline]
[Order article via Infotrieve]
- Aisen PS, Saumier D., Briand R., et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67:1757-1763.[Abstract/Free Full Text]
- Aisen PS, Gauthier S., Vellas B., et al. Alzhemed: A Potential Treatment for Alzheimer's Disease. Curr Alz Res. 2007;4:473-478.[CrossRef]
- Necula M., Kayed R., Milton S., Glabe CG Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem. 2007;282: 10311-10324.[Abstract/Free Full Text]
- Santa-Maria I., Hernández F., Del Rio J., et al. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol Neurodegener. 2007;2:17.[CrossRef][Medline]
[Order article via Infotrieve]
- Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400: 173-177.[CrossRef][Medline]
[Order article via Infotrieve]
- Gilman S., Koller M., Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.[Abstract/Free Full Text]
- Brody DL, Holtzman DM Active and Passive Immunotherapy for Neurodegenerative Disorders. Annu Rev Neurosci. 2008;31:175-193.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452-457.[Web of Science][Medline]
[Order article via Infotrieve]
- Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2006;9: 309-317.[Medline]
[Order article via Infotrieve]
- Avila J., Hernández F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother. 2007;7:1527-1533.[CrossRef][Medline]
[Order article via Infotrieve]
- Hong M., Chen DC, Klein PS, Lee VM Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem. 1997;272:25326-25332.[Abstract/Free Full Text]
- Phiel CJ, Wilson CA, Lee VM, Klein PS GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003;423:435-439.[CrossRef][Medline]
[Order article via Infotrieve]
- Feyt C., Kienlen-Campard P., Leroy K., et al. Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. J Biol Chem. 2005;280:33220-33227.[Abstract/Free Full Text]
- Forlenza OV, Spink JM, Dayanandan R., et al. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm. 2000;107:1201-1212.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tuszynski MH Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21: 179-189.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Eriksdotter Jönhagen M., Nordberg A., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998;9:246-257.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Tuszynski MH, Thal L., Pay M., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11:551-555.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Terry AV Jr, Buccafusco JJ The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306: 821-827.[Abstract/Free Full Text]
- Seabrook GR, Ray WJ, Shearman M., Hutton M. Beyond amyloid: the next generation of Alzheimer's diseasse therapeutics. Mol Interv. 2007;7:261-270.[Abstract/Free Full Text]
This version was published on April
1, 2009
American Journal of Alzheimer's Disease and Other Dementias®, Vol. 24, No. 2,
95-121 (2009)
DOI: 10.1177/1533317508328602

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|